HanlyJGO'KeeffeAGSuL, et al.The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology2016; 55(2): 252–262.
2.
VincentFBSaulep-EastonDFiggettWA, et al.The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev2013; 24(3): 203–215.
3.
FurieRRovinBHHoussiauF, et al.Two-year, randomized, Controlled trial of belimumab in lupus nephritis. N Engl J Med2020; 383(12): 1117–1128.
4.
MerrillJTNeuweltCMWallaceDJ, et al.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum2010; 62(1): 222–333.
5.
RovinBHFurieRLatinisK, et al.Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum2012; 64(4): 1215–1226.
6.
ContisAVanquaethemHTruchetetME, et al.Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clin Rheumatol2016; 35(2): 517–522.
7.
Gomez MendezLMCascinoMDGargJ, et al.Peripheral Blood B cell depletion after rituximab and Complete response in lupus nephritis. Clin J Am Soc Nephrol2018; 13(10): 1502–1509.
8.
KorbetSMSchwartzMMEvansJ, et al.Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol2007; 18(1): 244–254.
9.
WiseLMStohlW. Belimumab and rituximab in systemic lupus erythematosus: a Tale of Two B cell-Targeting Agents. Front Med2020; 7: 303.
10.
van SchaikMArendsEJSoonawalaD, et al.Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Trials2022; 23(1): 939.
